While its efficacy in hepatocellular carcinoma (HCC) is attributed to modulation of the TGFβ pathway (67), this mechanism is also involved in AML stem cell maintenance, supporting its potential for translation into leukemia treatment. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.